Nearly everyone is infected with Epstein-Barr virus at some point in childhood or young adulthood, usually with no symptoms worse than a sore throat or a mild case of mononucleosis that clears up and is forgotten. Decades later, a small fraction of those same people go on to develop multiple sclerosis, a chronic disease that attacks the protective coating around nerve fibers in the brain and spinal cord. Research built on one of the largest cohort studies ever assembled for the question has found that the connection between the two is far from coincidental. The work did not just find a statistical link; it tracked the order in which infection and disease occurred in the same people, which is what let researchers argue for the virus as a likely trigger rather than a bystander that happens to show up in blood tests of people who are already sick.
The Virus Almost Everyone Catches Before Adulthood
Epstein-Barr virus spreads easily through saliva, which is why it earned the nickname “the kissing disease” when it causes noticeable mononucleosis in teenagers and young adults. Most people are infected in early childhood without ever developing symptoms severe enough to be diagnosed, and the virus then goes dormant in the body for life, kept in check by the immune system rather than fully cleared. Because infection is so close to universal, doctors long struggled to connect it to any specific later disease, since a virus that infects almost everyone cannot obviously explain a condition that affects only a small share of the population. Multiple sclerosis itself typically appears in early adulthood, well after the initial viral infection has come and gone, which made the years-long gap between exposure and disease onset another obstacle to proving any direct relationship existed at all.
A Military Cohort That Tracked Infection Before Symptoms Appeared
Researchers at the Harvard T.H. Chan School of Public Health resolved that puzzle by studying a uniquely large and uniquely tracked population: more than 10 million young adults on active duty in the U.S. military, whose blood was drawn and stored periodically as a routine part of service. Among that group, 955 service members were diagnosed with multiple sclerosis over a 20-year period, and researchers were able to go back through each person’s stored blood samples to determine precisely when Epstein-Barr infection occurred relative to their first MS symptoms, according to the Harvard-led study of the cohort. That design let the team establish a sequence, infection first and disease years later, rather than relying on a snapshot that could not distinguish cause from coincidence.
A 32-Fold Jump in Risk After Infection
The result was a risk increase large enough to stand out clearly against statistical noise: the risk of developing multiple sclerosis rose 32-fold after Epstein-Barr infection, while infection with other common viruses transmitted in similar ways, including cytomegalovirus, produced no comparable increase, according to the peer-reviewed study published in Science. A 32-fold increase is unusually large for any infectious trigger tied to a chronic disease, and the specificity of the finding, with a similar virus producing no effect at all, made it difficult to explain away as a byproduct of some other shared risk factor among people who happened to get sick more often in general.
Why a Common Infection and a Rare Disease Are Not a Contradiction
Epstein-Barr virus infects more than 95 percent of adults worldwide, while multiple sclerosis remains a comparatively rare diagnosis, affecting under 1 percent of the population even among those who carry the virus. Researchers reconcile that gap by treating Epstein-Barr as a necessary trigger rather than a sufficient cause on its own: the virus appears to be required to set the disease process in motion in genetically susceptible individuals, but something else, whether genetic predisposition, another environmental exposure, or an unusual immune response to the virus itself, determines which infected people actually go on to develop MS. That framing also fits with decades of earlier, smaller studies that had noticed an association between Epstein-Barr antibodies and MS without being able to prove which came first.
What the Finding Opens Up for Prevention
Because more than 95 percent of MS cases in the studied cohort followed Epstein-Barr infection, researchers have argued that a large share of multiple sclerosis could theoretically be prevented by stopping the initial infection altogether, which is part of why work on an Epstein-Barr vaccine has drawn renewed attention since the study’s publication. No vaccine against the virus is yet in routine use, and turning a strong statistical association into an approved prevention strategy still requires years of additional trial work. The finding has nonetheless reframed how researchers study MS’s origins, shifting some effort away from treating the disease only after it appears and toward understanding, and eventually interrupting, the viral trigger that seems to set it in motion decades earlier. Until a vaccine or antiviral strategy exists, the practical takeaway for most people is limited, since Epstein-Barr infection is nearly universal and unavoidable, but the research has already reshaped how scientists explain why MS clusters the way it does across different populations and geographic regions.
This article was produced with the assistance of AI and reviewed by Morning Overview editors.
More from Morning Overview
